Digestive Diseases and Sciences

, 54:1835 | Cite as

The Safety of Histamine 2 (H2) Blockers in Pregnancy: A Meta-analysis

  • Simerpal Kaur Gill
  • Lisa O’Brien
  • Gideon Koren
Original Article

Abstract

Heartburn and acid reflux increase the severity of nausea and vomiting of pregnancy, and may lead to more serious medical conditions. The fetal safety of histamine 2 (H2) blockers, the most common antireflux medication, during pregnancy needs to be determined. The aim herein is to determine the fetal safety of H2 blockers during pregnancy through systematic review. All original research assessing the safety of H2 blockers in pregnancy was sought. Data included congenital malformations, spontaneous abortions, preterm delivery, and small for gestational age. A random-effects model combined results. With data from 2,398 exposed and 119,892 nonexposed to H2 blockers, overall odds ratio was 1.14 [0.89, 1.45]. Further analysis revealed no increased risks for spontaneous abortions, preterm delivery, and small for gestational age with odds ratios and 95% confidence intervals (CIs) of 0.62 [0.36–1.05], 1.17 [0.94, 1.147], and 0.28 [0.06, 1.22], respectively. H2 blockers can be used safely in pregnancy.

Keywords

H2 blockers Acid reflux GERD Pregnancy Malformations 

Notes

Acknowledgment

Motherisk NVP helpline is supported by an unrestricted grant from Duchesnay, Inc. Canada. GK is holder of the Research Leadership for Better Pharmacotherapy during Pregnancy and Lactation (Hospital for Sick Children) and the Ivey Chair in Molecular Toxicology (Department of Medicine, University of Western Ontario).

References

  1. 1.
    Baron T, Ramirez B, Richter J. Gastrointestinal motility disorders in pregnancy. Ann Intern Med. 1993;118(5):366–375.PubMedGoogle Scholar
  2. 2.
    Ali R, Egan L. Gastroesophageal reflux disease in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):793–806. doi:10.1016/j.bpg.2007.05.006.PubMedCrossRefGoogle Scholar
  3. 3.
    Broussard C, Richter J. Treating gastro-oesophageal reflux during pregnancy and lactation: what are the safest therapy options? Drug Saf. 1998;19(4):325–337. doi:10.2165/00002018-199819040-00007.PubMedCrossRefGoogle Scholar
  4. 4.
    Mahadevan U. Gastrointestinal medications in pregnancy. Best Pract Res Clin Gastroenterol. 2007;21(5):849–877. doi:10.1016/j.bpg.2007.06.002.PubMedCrossRefGoogle Scholar
  5. 5.
    Richter J. Review article: The management of heartburn in pregnancy. Aliment Pharmacol Ther. 2005;22:749–757. doi:10.1111/j.1365-2036.2005.02654.x.PubMedCrossRefGoogle Scholar
  6. 6.
    Castro L. Reflux esophagitis as the cause of heartburn in pregnancy. Am J Obstet Gynecol. 1967;98:1–10.Google Scholar
  7. 7.
    Marrero J, Goggin P, de Caestecker J, Pearce J, Maxwell J. Determinants of pregnancy heartburn. Br J Obstet Gynaecol. 1992;99:731–734.PubMedGoogle Scholar
  8. 8.
    Everson G. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am. 1992;21(4):751–756.PubMedGoogle Scholar
  9. 9.
    Rey E, Rodriguez-Artalejo F, Herraiz M, et al. Gastroesophageal reflux symptoms during and after pregnancy: a longitudinal study. Am J Gastroenterol. 2007;102:2395–2400. doi:10.1111/j.1572-0241.2007.01452.x.PubMedCrossRefGoogle Scholar
  10. 10.
    Bor S, Kitapcioglu G, Dettmar P, Baxter T. Association of heartburn during pregnancy with the risk of gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2007;5(9):1035–1039. doi:10.1016/j.cgh.2007.05.003.PubMedCrossRefGoogle Scholar
  11. 11.
    Gill SK, Maltepe C, Koren G. The effect of heartburn and acid refux on the severity of nausea and vomiting of pregnancy. Can J Gastroenterol (accepted).Google Scholar
  12. 12.
    Downs S, Black N. The feasibility of creating a checklist for the assessment of methodological quality of both randomized and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52:377–384.PubMedCrossRefGoogle Scholar
  13. 13.
    Garbis H, Elefabt E, Diav-Citran O, et al. Mathieu-Nolf M: Pregnancy outcome after exposure to ranitidine and other H-2 blockers: a collaborative study of the European Network of Teratology Information Services. Reprod Toxicol. 2005;19:453–458. doi:10.1016/j.reprotox.2004.09.002.PubMedCrossRefGoogle Scholar
  14. 14.
    Magee L, Inocencion G, Kamboj L, Rossetti F, Koren G. Safety of first trimester exposure to H2 blockers: a prospective cohort study. Dig Dis Sci. 1996;41(6):1145–1149. doi:10.1007/BF02088230.PubMedCrossRefGoogle Scholar
  15. 15.
    Ruigomez A, Rogriguez L, Cattaruzzi C, et al. Use of cimetidine, omeprazole and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol. 1999;150(5):476–481.PubMedGoogle Scholar
  16. 16.
    Matok I, Gorodischer R, Koren G, Levy A. The safety of intrauterine exposure to H2-blockers: a study by linking computerized databases. Proceedings of the 11th Congress of the European Society for Developmental Pharmacology. Rotterdam, The Netherlands, June 2008, Abstract 45.Google Scholar
  17. 17.
    Colin Jones DG, Langman MJ, Lawson DH, Vessey MP. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidly report. Q J Med. 1985;54:253–268.PubMedGoogle Scholar
  18. 18.
    Kallen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstet Gynaecol. 1998;105(8):877–881.PubMedGoogle Scholar
  19. 19.
    Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol. 1998;179(3):727–730. doi:10.1016/S0002-9378(98)70072-9.PubMedCrossRefGoogle Scholar
  20. 20.
    Koren G, Zemlickis D. Outcome of pregnancy after 1st trimester exposure to H2 receptor antagonists. Am J Perinatol. 1991;8:37–38.PubMedCrossRefGoogle Scholar
  21. 21.
    Larson J, Patatanian E, Miner P, Rayburn W, Robinson M. Double-blind, placebo controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol. 1997;90(1):83–87. doi:10.1016/S0029-7844(97)00126-9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Simerpal Kaur Gill
    • 1
    • 2
  • Lisa O’Brien
    • 1
    • 3
  • Gideon Koren
    • 1
    • 2
    • 3
  1. 1.The Motherisk Program, The Hospital for Sick ChildrenTorontoCanada
  2. 2.Department of PharmacologyUniversity of TorontoTorontoCanada
  3. 3.Institute of Medical Science, University of TorontoTorontoCanada

Personalised recommendations